Envoy Medical, Inc. (COCH): who owns it and who trades it
As of Nov 16, 2026, COCH insiders reported 6 purchases worth $8.2M in the last 12 months. The largest buyer was Glen A Taylor (10% owner), with $7.5M. 1 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Envoy Medical
From the latest filingsOverall: more buying than selling. Insiders and famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns COCH
32 funds and institutions reported COCH shares worth $19.9M at the end of Q2 2026, about 33% of the company. The largest holder is Nantahala Capital Management, LLC with 19.9%.
Funds and institutions (13F) 33%Everyone else 67%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 15.30M | 19.90% | $11.9M | +100% |
| Bleichroeder LP | 6.25M | 8.13% | $5M | No change |
| Vanguard Capital Management LLC | 880,214 | 1.14% | $697K | -0% |
| DSG Capital Advisors, LLC | 625,000 | 0.81% | $474K | No change |
| Geode Capital Management, LLC | 541,729 | 0.70% | $429K | +4% |
| Focus Partners Wealth | 425,310 | 0.55% | $337K | +100% |
| Vanguard Fiduciary Trust Co | 296,679 | 0.39% | $235K | +1% |
| UBS Group AG | 190,838 | 0.25% | $151K | +171% |
| Arcus Capital Partners, LLC | 187,573 | 0.24% | $149K | No change |
| ExodusPoint Capital Management, LP | 182,354 | 0.24% | $144K | New |
| Northern Trust Corp | 109,466 | 0.14% | $86.7K | -1% |
| Morgan Stanley | 90,921 | 0.12% | $72K | +23% |
| CIBC Bancorp USA Inc. | 77,887 | 0.10% | $61.7K | No change |
| LPL Financial LLC | 48,401 | 0.06% | $38.3K | +70% |
| Jane Street Group, LLC | 31,223 | 0.04% | $24.7K | New |
| Meteora Capital, LLC | 28,051 | 0.04% | $22.2K | No change |
| State Street Corp | 23,872 | 0.03% | $18.9K | No change |
| XTX Topco Ltd | 17,146 | 0.02% | $13.6K | New |
| Afg Fiduciary Services Limited Partnership | 12,000 | 0.02% | $9K | No change |
| BlueStem Wealth Partners, LLC | 10,454 | 0.01% | $8.3K | No change |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, COCH insiders reported $8.2M of open-market purchases and $0 of sales.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Feb 12, 2026 | Mona Chetan Patel | Director | Purchase | 312,500 | $0.40 | $125K | Form 4 |
| Feb 12, 2026 | Robert Potashnick | CFO | Purchase | 212,500 | $0.40 | $85K | Form 4 |
| Feb 12, 2026 | Susan Kantor | Director | Purchase | 96,150 | $0.40 | $38.5K | Form 4 |
| Feb 12, 2026 | Charles Brynelsen | Director | Purchase | 1.00M | $0.40 | $400K | Form 4 |
| Feb 12, 2026 | Brent T. Lucas | CEO | Purchase | 62,500 | $0.40 | $25K | Form 4 |
| Feb 12, 2026 | Glen A Taylor | 10% owner | Purchase | 18.75M | $0.40 | $7.5M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Glen A Taylor | 10% owner | $7.5M | – | Feb 12, 2026 |
| Charles Brynelsen | Director | $400K | – | Feb 12, 2026 |
| Mona Chetan Patel | Director | $125K | – | Feb 12, 2026 |
| Robert Potashnick | Interim CFO | $85K | – | Feb 12, 2026 |
| Susan Kantor | Director | $38.5K | – | Feb 12, 2026 |
| Brent T. Lucas | Chief Executive Officer, Director | $25K | – | Feb 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
COCH short interest
Low short interest. 0.1% of COCH shares are sold short: about 1 share in 859. Over the last 12 reports the number of shares short went down 93%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 89,915 COCH shares were sold short, 0.1% of the shares outstanding, down 84.4% from the report before. At the average daily volume of 33,639 shares, buying them all back would take about 2.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 89,915 | 0.12% | -84% | 33,639 | 2.7 |
| Oct 15, 2026 | 577,087 | 0.75% | +16% | 76,811 | 7.5 |
| Sep 30, 2026 | 497,969 | 0.65% | -6% | 62,533 | 8.0 |
| Sep 15, 2026 | 529,130 | 0.69% | -13% | 49,045 | 10.8 |
| Aug 31, 2026 | 605,798 | 0.78% | -30% | 58,310 | 10.4 |
| Aug 14, 2026 | 865,248 | 1.12% | -11% | 155,161 | 5.6 |
| Jul 31, 2026 | 976,338 | 1.27% | +11% | 286,512 | 3.4 |
| Jul 15, 2026 | 879,886 | 1.14% | -11% | 390,872 | 2.2 |
| Jun 30, 2026 | 983,762 | 1.28% | -14% | 1.30M | 1.0 |
| Jun 15, 2026 | 1.15M | 1.49% | -1% | 127,092 | 9.0 |
| May 29, 2026 | 1.15M | 1.50% | -8% | 132,612 | 8.7 |
| May 15, 2026 | 1.26M | 1.63% | -7% | 108,991 | 11.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Envoy Medical company events
Envoy Medical filed 21 reports on Form 8-K in the last 12 months, 9 of them about an important change (leadership, listing, auditor). The latest was on Nov 5, 2026.
- Nov 5, 2026ResultsReleased financial results. Filing
- Oct 27, 2026SharesChanged the rights of its shareholders. Filing
- Oct 16, 2026VoteReported shareholder vote results. Filing
- Oct 7, 2026AnnouncementEnvoy Medical, Inc., a Delaware corporation, entered into a Dismissal Agreement regarding litigation in the Delaware Court of Chancery with Atlas Merchant Capital SPAC Fund I LP related to Atlas’ allegation that it was not allowed to redeem its shares of Class A Common Stock in the Company’s… Filing
- Aug 27, 2026LeadershipEnvoy Medical, Inc. appointed Robert Potashnick to serve as the Company’s Chief Accounting Officer and Vice President of Finance. Filing
- Aug 10, 2026ResultsReleased financial results. Filing
- Jun 30, 2026AgreementEnded an important agreement. Filing
- Jun 25, 2026LeadershipThe Compensation Committee of the Board of Directors of Envoy Medical, Inc., approved certain changes to the compensation of the Company’s Chief Executive Officer, Brent Lucas. Filing
- May 22, 2026ListingAs previously disclosed, on November 19, 2025, Envoy Medical, Inc., received a staff determination notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC, informing the Company that its Class A Common Stock, par value $0.0001 per share, had failed to comply with the $1.00… Filing
- May 18, 2026LeadershipEnvoy Medical, Inc. held its 2026 Annual Meeting of Stockholders. Filing
- May 11, 2026ResultsReleased financial results. Filing
- Apr 21, 2026LeadershipUpon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors of Envoy Medical, Inc., the Board appointed Charles S. McKhann to serve as a Class I director, with an initial term expiring at the Company’s 2027 annual meeting of stockholders. Filing
- Mar 31, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
- Mar 27, 2026ResultsReleased financial results. Filing
- Feb 27, 2026ListingEnvoy Medical, Inc. received a letter from the Nasdaq Listing Qualifications Hearings office confirming that the Company has evidenced compliance with Nasdaq Listing Rule 5550(b)(2) in compliance with the Nasdaq Hearing Panel’s letter dated October 23, 2025. Filing
- Feb 13, 2026AgreementEnvoy Medical, Inc., a Delaware corporation, commenced a best efforts public offering of an aggregate of (i) 47,946,150 shares of the Company’s Class A Common Stock, par value $0.0001 per share, (ii) 27,053,850 pre-funded warrants to purchase 27,053,850 shares of Common Stock, (iii) 45,000,000… Filing
- Feb 11, 2026LeadershipThe Compensation Committee of the Board of Directors of Envoy Medical, Inc. approved the issuance of stock options to the Company’s Chief Executive Officer, Brent Lucas, and its Interim Chief Financial Officer, Robert Potashnick under the Company’s 2023 Equity Incentive Plan, as amended. Filing
- Dec 29, 2025AgreementEnvoy Medical, Inc. has previously issued Stock Purchase Warrants (as amended to date, the “ Shortfall Warrants ”) to Meteora Special Opportunity Fund I, LP, Meteora Capital Partners, LP, Meteora Select Trading Opportunities Master, LP and Meteora Strategic Capital, LLC (“ MSC ” and, collectively… Filing
- Dec 16, 2025AnnouncementShared information with investors. Filing
- Dec 3, 2025VoteReported shareholder vote results. Filing
- Nov 25, 2025ListingEnvoy Medical, Inc. received a staff determination notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC, informing the Company that its Class A Common Stock, par value $0.0001 per share, has failed to comply with the $1.00 minimum bid price required for continued listing… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Envoy Medical financials
Famous investors that hold COCH
1 of the 50 well-known investors we track reported holding COCH in their latest 13F filing. The largest position is Ken Griffin's, worth $19.3K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 28,278 | $19.3K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Envoy Medical, Inc. (COCH) stock
Who owns the most COCH stock?
The largest reported owner of Envoy Medical, Inc. (COCH) is Nantahala Capital Management, LLC, with 19.9% of the company. In total, 32 funds and institutions reported holding COCH at the end of Q2 2026, together about 33% of the shares. See the largest owners.
Are COCH insiders buying or selling?
In the last 12 months, COCH insiders reported 6 open-market purchases worth $8.2M and no sales. The latest trade was on Feb 12, 2026. See every trade.
What is the short interest in COCH?
As of Oct 30, 2026, 89,915 COCH shares were sold short, 0.1% of the shares outstanding, down 84.4% from the report before. At the average daily volume of 33,639 shares, buying them all back would take about 2.7 trading days (days to cover). See the history.
Which famous investors hold COCH?
1 of the 50 well-known investors we track reported COCH in their latest 13F filing, including Ken Griffin. The largest position is worth $19.3K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.